Bifidobacterium
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Bifidumbacterin forte - normalizing the intestinal microflora, immunomodulatory agent.
The action of the drug is due to the high concentration of bifidobacteria (Bifidobacterium bifidum) sorbed on particles of Activated charcoal, which are antagonists of a wide range of pathogenic (Shigella, Salmonella, S. aureus, etc.) and conditionally pathogenic microorganisms (Proteus, Klebsiella, etc.).
Microcolonies of sorbed bifidobacteria provide for the rapid restoration of normal microflora, which, being a natural biosorbent, accumulates in a significant amount the toxic substances from the outside or formed in the body.
Sorbed bifidobacteria activate the recovery processes in the mucous membranes, parietal digestion, the synthesis of vitamins and amino acids, increase the body's immune defense.
Indications
As monotherapy or as part of complex therapy:
- Intestinal dysbiosis.
- Acute intestinal infections of the established (shigellosis, salmonellosis, staphylococcal enterocolitis, rotavirus infection) and of unidentified etiology.
- Food toxicoinfection.
- SARS.
Chronic diseases with damage to the gastrointestinal tract, accompanied by intestinal dysbacteriosis:
- Peptic ulcer and duodenal ulcer.
- Pancreatitis.
- Cholecystitis.
- Diseases of the liver and biliary tract.
- Chronic constipation.
- Malabsorption syndrome.
- Allergic diseases accompanied by intestinal dysbiosis.
- Pneumonia, acute and chronic bronchitis, inflammatory diseases of the urogenital tract, accompanied by intestinal dysbacteriosis.
- Intestinal dysbiosis caused by taking antibiotics, antibacterial drugs, hormones, NSAIDs.
- Diarrhea in patients who received long-term treatment with antibiotics and other antibacterial drugs.
- Correction of intestinal microbiocenosis and prevention of purulent-inflammatory diseases in surgical patients during the period of preoperative preparation and after operations on the intestine, liver, pancreas.
In order to prevent:
- Intrahospital infections in maternity homes and hospitals.
- Dysbacteriosis in frequently ill SARS children and adults.
Composition
Active substance: bifidobacteria (B. bifidum), sorbed on Activated charcoal - at least 50 million (5 × 107) SOME.
Auxiliary substance: lactose monohydrate
Bifidobacterium is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
Bifidumbacterin forte | Partner | Russia | tea bags |
Bifidumbacterin | Partner | Russia | tea bags |
Florin forte | Partner | Russia | capsules |
Linex | Sandoz | Switzerland | drops |
Linex | Sandoz | Switzerland | sachet |
Bifidumbacterin | Ecopolis | Russia | vials |
Bifidumbacterin | Ecopolis | Russia | capsules |
Bifidumbacterin forte | Partner | Russia | capsules |
Bifiform | Ferrosan S.R.L | Denmark | bottle |
Florin forte | Partner | Russia | tea bags |
Probifor | Partner | Russia | capsules |
Bifidumbacterin-1000 | Ecko Plus | Russia | pills |
Bifilis | VIGEL) (Enzyme | Russia | vials |
Probifor | Partner | Russia | powder |
Bifidumbacterin | Lanafarm | Russia | pills |
No customer reviews for the moment.
Dosage and Administration
For oral use during the meal, if necessary, regardless of the meal.
Powder Before use, mixed with liquid food, preferably fermented milk product, newborns and infants - with breast milk or formula for artificial feeding. You can mix the drug with 30-50 ml of boiled water at room temperature, this forms a cloudy suspension with particles of black sorbent. The resulting water suspension should be drunk, not achieving complete dissolution.
Acute intestinal infection, food toxicoinfection, diarrhea: children up to 6 months - 1 pack. 2 times a day; older than 6 months - 1 pack. 3-4 times a day (possibly with an interval of 2-3 hours), a course of treatment of 2-3 days, with the preservation of symptoms, the course of treatment is extended to 4-5 days; from 5 to 7 years - 1 caps. 3-4 times a day (possibly with an interval of 2-3 hours), a course of treatment of 2-3 days, with the preservation of symptoms, the course of treatment is extended to 4-5 days; over 7 years old and adults - 2–3 pack./caps. 2 times a day, the course of treatment for 3-5 days.
Termination of diarrhea in the early stages of the disease: adults - 3 pack. / caps. 2 times a day with an interval of 30–60 minutes. The dosage can be increased to 6 pack./caps. Once a day, the course of treatment is 1-3 days.
Chronic pathology of the digestive tract, irritable bowel syndrome: children from 5 years - once 3 caps. during the evening meal; children and adults - once 3 pack. during the evening meal; adults - maybe 3 caps. once or for 2 packs / caps. 2 times a day. The course of treatment is 5–15 days. In severe disease: children from 1 year to 5 years - up to 6 pack. in a day; children from 5 years and adults - up to 6 pack./caps. per day, the course is up to 30 days.
Comprehensive treatment of SARS and flu: children up to 5 years old from the 1st – 2nd day of the disease - 1 pack. 3 times a day; children older than 5 years and adults from the 1st – 2nd day of the disease - 1 pack./caps. 3 times a day, the course of treatment - 2 days.
Surgical patients, pregnant women in preparation for cesarean section to reduce postoperative complications: Before surgery, children under 5 years old - 1 pack. 3 times a day for 2-3 days; older than 5 years and adults - 1 pack./caps. 3 times a day for 2-3 days; Persons suffering from intestinal dysbiosis, treated with antibiotics and chemotherapy drugs, the preoperative course is extended to 7 days; From the 2nd to the 7th day after the operation, children under 5 years old - 1 pack each, children over 5 years old and adults 1 pack / caps. 3 times a day for 2–3 days, according to indications - up to 7–10 days.
Dysbacterioses of various etiologies, chronic intestinal infections, patients with immunodeficiency states, skin diseases, as well as improvement of the adaptation period in newborns (including premature infants): premature newborns - 1 pack. 1-2 times a day; full-term newborns and children up to 3 years old - 1 pack. 2 times a day; children from 3 to 5 years old - 1 pack. 3 times a day; from 5 to 7 years - 1 pack. / caps. 3 times a day; over 7 years old and adults - 2–3 pack./caps. 2 times a day. The course of treatment is 7-10 days.
For preventive purposes: children under 1 year old on 1 package 1 time per day, all the rest 1-2 packages / capsule 1-2 times per day. Preventive course is carried out 10-15 days 2-3 times a year.
Contraindications
Individual intolerance to the drug.
Bifidumbacterin should be administered with caution to children with lactase deficiency.
Drug interactions
At the same time taking Bifidumbacterin Forte with vitamins (especially group B), the effect of the drug is enhanced.
When taking antibiotics, the recommended interval between taking an antibiotic and Bifidumbacterin Forte is 3 to 4 hours.
Pregnancy and Lactation
Bifidumbacterin forte allowed for use in women during pregnancy and breastfeeding.
Special instructions
The drug should not be used in violation of the integrity of individual packaging, violation of labeling.
For dilution of the drug do not use water with a temperature above 40C and do not store bifidumbacterin forte in diluted form.
- Brand name: Bifidumbacterin forte
- Active ingredient: Bifidobacterium bifidum
- Dosage form: Powder for oral administration.
- Manufacturer: Partner
- Country of Origin: Russia
Studies and clinical trials of Bifidobacterium (Click to expand)
- Stability of recombinant plasmids on the continuous culture of Bifidobacterium animalis ATCC 27536
- Optimal thermotolerance of Bifidobacterium bifidum in gellan–alginate microparticles
- Einsatz der gnotobiotischen Ratte zur Erfassung der in vivo-Aktivität von Bifidobacterium-β-Galaktosidase
- Wandlungen innerhalb Lactobacillus- und Bifidobacterium-Species
- Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of γδT and regulatory T cells of intestinal intraepithelial lymphocytes
- Antigen-presenting cells exposed to Lactobacillus acidophilus NCFM, Bifidobacterium bifidum BI-98, and BI-504 reduce regulatory T cell activity
- Bifidobacterium lactis inhibits NF-κB in intestinal epithelial cells and prevents acute colitis and colitis-associated colon cancer in mice
- Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosal immunization in a mouse model
- PCR monitoring of Lactobacillus and Bifidobacterium dynamics in fermentations by piglet intestinal microbiota
- Effect of enzymatic hydrolysis of proteins on growth of Bifidobacterium bifidus in milk
- Antioxidative capacity produced by Bifidobacterium- and Lactobacillus acidophilus-mediated fermentations of konjac glucomannan and glucomannan oligosaccharides
- Isolation and characterisation of an oxygen, acid and bile resistant Bifidobacterium animalis subsp. lactis Qq08
- Synbiotic promotion of epithelial proliferation by orally ingested encapsulated Bifidobacterium breve and raffinose in the small intestine of rats
- Primary structure of ten galactosides formed by transglycosylation during lactose hydrolysis by Bifidobacterium bifidum
- Structural studies on a cell wall polysaccharide from Bifidobacterium longum YIT4028
- Structure of a galactan from cell walls of Bifidobacterium catenulatum YIT4016
- Ferrous iron uptake by Bifidobacterium bifidum var. Pennsylvanicus: The effect of metals and metabolic inhibitors
- Effects of Mg2+ and Ca2+ on Fe2+ uptake by Bifidobacterium thermophilum
- Epidural abscess due to Streptococcus milleri and Bifidobacterium species
- Enhancement of growth rate and β-galactosidase activity, and variation in organic acid profile of Bifidobacterium animalis subsp. lactis Bb 12